List of Excipients in Branded Drug NORLIQVA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
CMP Pharma Inc	NORLIQVA	amlodipine	46287-035	ALCOHOL
CMP Pharma Inc	NORLIQVA	amlodipine	46287-035	BUTYLATED HYDROXYANISOLE
CMP Pharma Inc	NORLIQVA	amlodipine	46287-035	GLYCERIN
CMP Pharma Inc	NORLIQVA	amlodipine	46287-035	MALTITOL
CMP Pharma Inc	NORLIQVA	amlodipine	46287-037	BUTYLATED HYDROXYANISOLE
CMP Pharma Inc	NORLIQVA	amlodipine	46287-037	GLYCERIN
CMP Pharma Inc	NORLIQVA	amlodipine	46287-037	PROPYLENE GLYCOL

Norliqva Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Norliqva is a 1 mg/mL oral solution of amlodipine besylate developed for patients who cannot reliably use tablets. Its commercial position depends less on new pharmacology than on liquid-dose flexibility, swallowing support, pediatric administration, and access for patients using enteral feeding tubes. The formulation uses a relatively simple excipient system: glycerin, hydroxyethylcellulose, sodium benzoate, sucralose, citric acid, and purified water.[1]

The main commercial constraint is the low cost and broad availability of generic amlodipine tablets. Norliqva therefore needs to capture administration-driven value rather than compete on active-ingredient cost. The strongest opportunities are pediatric hypertension, dysphagia, geriatric care, institutional dispensing, and patients requiring individualized low doses.

What is Norliqva and how does its formulation differ from amlodipine tablets?

Norliqva is an FDA-approved oral solution containing amlodipine besylate equivalent to amlodipine 1 mg/mL. The product is administered by mouth and is intended to provide the same active drug used in conventional amlodipine tablets.[1]

Attribute	Norliqva	Conventional amlodipine tablets
Active ingredient	Amlodipine besylate	Amlodipine besylate
Strength	1 mg/mL	Commonly 2.5 mg, 5 mg, and 10 mg
Dosage form	Oral solution	Tablet
Primary differentiation	Liquid administration and dose measurement	Low-cost solid oral dosage
Pediatric use	Label includes pediatric hypertension in patients 6 years and older	Tablet administration may be difficult for some patients
Dose flexibility	Allows measured doses below tablet strengths	Limited by available tablet strengths and splitting
Likely distribution	Retail, specialty, institutional, and specialty pharmacy channels	Broad generic retail distribution

Norliqva does not create a new amlodipine mechanism or a new therapeutic class. Its value proposition is administration. A 1 mg/mL concentration permits 2.5 mg, 5 mg, and 10 mg doses to be delivered as 2.5 mL, 5 mL, and 10 mL, respectively. It also supports smaller dose adjustments where tablets are inconvenient to split.

What excipients are used in Norliqva?

Norliqva’s listed inactive ingredients are citric acid, glycerin, hydroxyethylcellulose, sodium benzoate, sucralose, and purified water.[1]

Excipient	Formulation function	Commercial relevance
Purified water	Primary vehicle	Supports aqueous oral-solution delivery
Glycerin	Cosolvent, humectant, mouthfeel modifier	Helps reduce harshness and improves liquid texture
Hydroxyethylcellulose	Viscosity modifier and suspending or thickening aid	Supports dose uniformity, pour control, and oral feel
Sodium benzoate	Preservative	Helps control microbial growth in a multidose aqueous product
Citric acid	pH adjustment and acidulant	Supports chemical stability and flavor profile
Sucralose	High-intensity sweetener	Improves acceptability without adding substantial sugar

The excipient system is commercially efficient because it uses familiar, low-cost materials rather than a complex lipid, polymeric, or nanoparticle platform. That reduces manufacturing complexity and may simplify scale-up, supplier qualification, and regulatory maintenance.

The formulation strategy appears designed around four objectives:

1. Maintain chemical and microbiological stability in an aqueous multidose product.
2. Improve palatability for pediatric and adult patients.
3. Produce a pourable liquid with adequate dose uniformity.
4. Avoid the operational burden associated with reconstituted suspensions.

How does Norliqva’s excipient strategy support commercial differentiation?

The excipient system creates product value through usability rather than pharmacodynamic superiority.

Palatability and adherence

Sucralose addresses the bitterness or unpleasant taste that can reduce acceptance of oral cardiovascular medicines. Glycerin can improve mouthfeel and reduce the perception of a sharp aqueous formulation. Taste is particularly relevant in pediatric hypertension, where repeated administration affects adherence and caregiver acceptance.

A liquid formulation still requires sensory optimization. Sweetness alone does not guarantee acceptability. The finished product must control bitterness, aftertaste, viscosity, and mouth coating. A follow-on product could compete through flavor selection, reduced sweetness, lower viscosity, or improved compatibility with feeding devices.

Dose flexibility

At 1 mg/mL, Norliqva enables measured dosing without tablet splitting or crushing. This is relevant when clinicians titrate therapy, when patients require doses below available tablet strengths, or when caregivers administer medicine to children.

The product can also reduce dosing errors associated with extemporaneous tablet manipulation. That advantage is strongest where the liquid is dispensed with a calibrated oral syringe and the prescribing instructions specify milliliters clearly.

Microbial protection

Sodium benzoate provides preservative protection in a water-based multidose product. The use of citric acid indicates that pH control is part of the stability and preservation strategy. This combination can support shelf life after opening, but the commercial product still depends on validated in-use stability, container closure integrity, and dosing-device performance.

Viscosity and dose uniformity

Hydroxyethylcellulose is important for liquid handling. Excessive viscosity can slow withdrawal through an oral syringe and leave residual product in the bottle or device. Insufficient viscosity can increase splashing, dosing variability, and poor mouthfeel.

For a solution rather than a suspension, the key formulation target is uniform concentration throughout the container. A thickener may still influence pour behavior and patient handling even when it is not required to keep drug particles suspended.

What are the strongest commercial opportunities for Norliqva?

Pediatric hypertension

The pediatric market is the clearest strategic opportunity. The FDA labeling for Norliqva includes use in pediatric patients 6 years and older with hypertension.[1] Many children have difficulty swallowing tablets, and liquid dosing can reduce the need for tablet crushing or manipulation.

The opportunity is constrained by the relatively small treated population and by the availability of compounded amlodipine liquids. Norliqva can compete by offering an FDA-approved, standardized product with labeled strength, validated manufacturing, and defined storage conditions.

Dysphagia and geriatric care

Older adults with stroke-related dysphagia, neurodegenerative disease, frailty, or polypharmacy may have difficulty swallowing solid dosage forms. Norliqva can be used where a liquid is clinically appropriate and may reduce caregiver burden.

This segment includes long-term-care facilities, assisted-living settings, home health, and specialty pharmacies. Institutional buyers will focus on unit cost, packaging, medication-administration time, storage, formulary placement, and whether the product can be dispensed through existing medication systems.

Enteral feeding

Patients using feeding tubes may require liquid medicines, but tube administration is product-specific. Commercial expansion in this segment depends on validated compatibility with common tube materials, flushing procedures, adsorption risk, dose recovery, and clogging performance.

A manufacturer that develops strong tube-administration data could differentiate the product without changing the active ingredient. Those data would also support hospital formulary adoption and clinical education.

Dose titration and low-dose administration

Liquid amlodipine is useful when a prescriber wants a dose that does not align neatly with tablet strengths. The opportunity is modest because amlodipine tablets are available in multiple strengths and can often be split. It becomes more relevant in pediatric care, frail patients, and patients sensitive to blood-pressure changes.

Combination therapy and adherence programs

A liquid amlodipine product could be paired commercially with adherence services, home blood-pressure monitoring, caregiver tools, or specialty pharmacy support. The formulation itself does not create a combination product, but its administration profile can support a broader hypertension-management offering.

How strong is Norliqva’s excipient and formulation protection?

Norliqva’s formulation protection is likely narrower than protection for a new chemical entity because the active ingredient, amlodipine, is long established and widely available in generic tablets.

Potential protection areas include:

• Specific excipient combinations.
• Defined pH ranges.
• Preservative systems.
• Taste-masking systems.
• Viscosity and dose-uniformity parameters.
• Container-closure and dosing-device combinations.
• Stability profiles for the commercial formulation.
• Manufacturing processes for producing a stable oral solution.
• Methods of administering amlodipine to patients who cannot swallow tablets.

The commercial value of these rights depends on claim scope and enforceability. A narrow claim covering a specific excipient ratio may be easy to design around. A broader claim covering a stable, palatable amlodipine oral solution may have greater commercial reach but may face stronger validity and obviousness challenges.

Excipient patents do not automatically block all generic or compounded alternatives. A competitor could use a different preservative, sweetener, thickener, flavor, or pH system. Regulatory exclusivity and Orange Book-listed patents must be analyzed separately from trade-secret manufacturing know-how.

What is the FDA regulatory status and Orange Book significance of Norliqva?

Norliqva was approved by the FDA under NDA 214439 as an oral solution of amlodipine besylate.[1] The product’s regulatory value comes from approval of a specific liquid formulation, not from exclusivity over amlodipine itself.

The key regulatory questions are:

Issue	Commercial implication
NDA approval	Establishes an FDA-reviewed liquid product with defined quality attributes
Amlodipine active ingredient	Limits product-level differentiation because the molecule is generic and mature
Oral-solution dosage form	May create a regulatory path for competitors using a different formulation
Pediatric labeling	Supports access to pediatric prescribers and institutional buyers
Orange Book listings	Determine whether listed patents may trigger Paragraph IV litigation
Regulatory exclusivity	Must be confirmed in current FDA databases and product records
Compounding	Creates a lower-cost alternative in selected clinical settings

The Orange Book should be reviewed for current patent listings, expiration dates, pediatric exclusivity, and any listed method-of-use or formulation patents.[2] The FDA label alone does not establish the complete patent estate. Patent status can change through expiration, delisting, terminal disclaimers, litigation, or settlement.

When does Norliqva lose exclusivity and face generic entry?

Norliqva’s generic-entry exposure is structurally high because amlodipine is a mature active ingredient and tablet alternatives are widely available. The main barrier for a direct competitor is not discovery of the molecule. It is development of an acceptable liquid product, demonstration of stability and dose uniformity, and selection of an appropriate FDA pathway.

Potential competitors may pursue:

• An ANDA for a pharmaceutically equivalent oral solution, if the regulatory requirements are met.
• A 505(b)(2) application for a differentiated liquid formulation or administration profile.
• A compounded formulation under applicable federal and state requirements.
• A hospital or institutional formulation strategy using pharmacy-compounded preparations.

A Paragraph IV challenge would depend on any unexpired Orange Book-listed patents covering Norliqva. The challenger would need to address formulation, manufacturing, method-of-use, and possible noninfringement positions. A generic tablet manufacturer could also compete indirectly by marketing tablets for crushing or dispersing, although that approach may not offer the same labeling or quality assurances as an approved liquid.

What manufacturing and intellectual-property barriers affect competing products?

The most relevant manufacturing barriers are practical rather than technological:

• Maintaining amlodipine concentration uniformity in a multidose bottle.
• Controlling pH and preservative effectiveness.
• Preventing degradation during shelf storage.
• Establishing suitable bottle and closure materials.
• Validating oral-syringe dose delivery.
• Demonstrating acceptable in-use stability.
• Managing flavor and sweetener interactions.
• Establishing compatibility with enteral feeding tubes.
• Scaling a viscous liquid without filling-speed or foaming problems.

Amlodipine besylate oral solution development may also require careful control of impurities, light exposure, container adsorption, and preservative performance. These issues can create meaningful know-how even where patent protection is limited.

Trade secrets may therefore be more valuable than narrow formulation patents. Process controls, flavor optimization, filling parameters, stability protocols, and device integration can delay practical competition even when formal patent barriers are weak.

How does Norliqva compare with generic amlodipine tablets?

Commercial factor	Norliqva	Generic tablets
Active-ingredient cost	Higher	Very low
Administration	Suitable for patients unable to swallow tablets	Requires tablet swallowing, splitting, or manipulation
Dose flexibility	High within the measuring-device range	Moderate
Pediatric suitability	Stronger for children unable to swallow tablets	Variable
Preservative exposure	Present	Generally not relevant in the same way
Storage and handling	Liquid-specific requirements	Simpler solid-dose logistics
Formulary economics	Requires clinical or operational justification	Usually preferred on price
Compounding alternative	Competes with pharmacy-made liquids	Not applicable in the same form
Differentiation potential	Taste, device, tube compatibility, and stability	Limited

Norliqva can command a premium only where the liquid dosage form solves a recognized administration problem. In routine adult hypertension, generic tablets will usually have the cost advantage.

What licensing and partnership opportunities exist for Norliqva?

Potential licensing opportunities are concentrated in delivery and distribution rather than new active-ingredient rights.

Pediatric and specialty pharmacy partnerships

A partner could provide pediatric prescribing access, caregiver education, flavor-support programs, and specialty dispensing. The strongest targets are organizations with established pediatric hypertension or complex-care networks.

Enteral-device collaborations

A tube-manufacturer or clinical nutrition partner could support compatibility studies, administration protocols, and hospital adoption. Such a collaboration could create defensible data even without a new patent.

Contract manufacturing

A qualified liquid-dose manufacturer could provide capacity, improve cost of goods, or support geographic expansion. Key diligence areas include preservative validation, liquid filling, container-closure testing, and supply continuity for hydroxyethylcellulose and sodium benzoate.

International licensing

The product may have opportunities in markets where pediatric liquid antihypertensives are limited. The regulatory value will vary by jurisdiction because approval of an amlodipine oral solution may not confer meaningful market exclusivity. Local pricing, compounding practices, and pediatric labeling requirements will determine attractiveness.

What is the revenue exposure and competitive outlook?

Revenue exposure is driven by the size of the administration-sensitive segment, not total amlodipine prescriptions. A small conversion rate among tablet users can produce volume, but the price premium is vulnerable to:

• Generic liquid entrants.
• Pharmacy compounding.
• Payer rejection or prior authorization.
• Institutional formulary restrictions.
• Tablet crushing or splitting.
• Physician preference for lower-cost products.

The strongest commercial defense is a package of product attributes: FDA-approved liquid labeling, reliable taste, calibrated dosing, pediatric data, tube compatibility, stable supply, and favorable reimbursement. Excipient composition alone is unlikely to sustain premium pricing unless it produces a clear clinical or operational advantage.

Key Takeaways

• Norliqva is a 1 mg/mL amlodipine besylate oral solution approved by the FDA under NDA 214439.
• Its excipient system uses glycerin, hydroxyethylcellulose, sodium benzoate, sucralose, citric acid, and purified water.
• The product’s primary value is administration flexibility, not a new pharmacologic effect.
• Pediatric hypertension, dysphagia, geriatric care, and enteral administration are the strongest target segments.
• Generic amlodipine tablets create substantial price pressure in routine adult hypertension.
• Formulation patents may protect specific excipient combinations, stability profiles, or manufacturing methods, but design-around risk is material.
• Trade-secret process controls and device compatibility data may provide more practical protection than narrow excipient claims.
• Current Orange Book listings, patent expiration dates, and any Paragraph IV litigation must be checked against the latest FDA records.
• Commercial success depends on payer access, institutional adoption, taste acceptance, dosing-device performance, and supply reliability.

FAQs

Can Norliqva be substituted for amlodipine tablets on a milligram-for-milligram basis?

The active drug is amlodipine, and the labeled concentration is 1 mg/mL. Substitution should follow the prescribing information and pharmacy requirements because the dosage form, measuring device, and administration instructions differ from tablets.[1]

Is Norliqva suitable for patients with diabetes who need a sugar-free liquid?

The listed sweetener is sucralose rather than sucrose.[1] Product labeling and clinical review should govern use in patients with specific excipient sensitivities or dietary restrictions.

Can Norliqva be administered through a feeding tube?

Tube administration should follow product-specific compatibility and administration instructions. A liquid dosage form does not by itself establish compatibility with every tube material or flushing protocol.

Could a competitor patent a different amlodipine liquid formulation?

Yes. A competitor may seek patents covering a different preservative system, taste-masking approach, pH range, viscosity profile, container, dosing device, or manufacturing process. Such patents would need to satisfy patentability and disclosure requirements.

Is pharmacy-compounded amlodipine liquid a direct substitute for Norliqva?

Compounded products may offer an alternative in selected settings, but they differ from an FDA-approved commercial product in formulation standardization, labeling, manufacturing oversight, stability data, and distribution model.

References

1. U.S. Food and Drug Administration. (2021). Norliqva (amlodipine besylate) oral solution prescribing information. NDA 214439.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm